| Q36123759 | 70 Gy or more: which dose for which prostate cancer? |
| Q30322084 | A comprehensive review of prostate cancer brachytherapy: defining an optimal technique. |
| Q40864212 | A survey of physics and dosimetry practice of permanent prostate brachytherapy in the United States |
| Q80297307 | Advances in brachytherapy |
| Q33674179 | American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer |
| Q73978374 | Analysis of biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer using dose-distribution variables and tumor control probability models |
| Q79149068 | Clinical correlates to PSA spikes and positive repeat biopsies after prostate brachytherapy |
| Q74434893 | Clinical impact of implementing the recommendations of AAPM Task Group 43 on permanent prostate brachytherapy using 125I. American Association of Physicists in Medicine |
| Q51061790 | Cryoablation as primary treatment for localized prostate cancer followed by penile rehabilitation. |
| Q58774971 | Diffusion weighted and dynamic contrast enhanced MRI as an imaging biomarker for stereotactic ablative body radiotherapy (SABR) of primary renal cell carcinoma |
| Q47944462 | Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. |
| Q33882539 | Early prostate cancer |
| Q77712025 | Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation |
| Q30665424 | Fitting tumor control probability models to biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer: pitfalls in deducing radiobiologic parameters for tumors from clinical data |
| Q73552559 | Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma |
| Q24235544 | Low-dose rate brachytherapy for men with localized prostate cancer |
| Q77738988 | Minimal criteria for the diagnosis of prostate cancer on needle biopsy |
| Q73567193 | Needle displacement during HDR brachytherapy in the treatment of prostate cancer |
| Q57582423 | PSA recurrence after brachytherapy for seed misplacement: a double-blind radiologic and pathologic work-up after salvage prostatectomy |
| Q73515944 | Palladium-103 brachytherapy for prostate carcinoma |
| Q34786857 | Pathologic evidence of dose-response and dose-volume relationships for prostate cancer treated with combined external beam radiotherapy and high-dose-rate brachytherapy |
| Q82480852 | Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer |
| Q33760215 | Permanent prostate seed implant brachytherapy: report of the American Association of Physicists in Medicine Task Group No. 64. |
| Q38710610 | Preliminary safety and efficacy results with robotic high-intensity focused ultrasound : A single center Indian experience |
| Q40844074 | Prognostic value of prostate specific antigen before, during and after radiotherapy |
| Q34539278 | Prostate brachytherapy has come of age: a review of the technique and results |
| Q36181798 | Prostate cryotherapy: more questions than answers |
| Q47827827 | Prostate-specific antigen (PSA) velocity and benign prostate hypertrophy predict for PSA spikes following prostate brachytherapy. |
| Q74816612 | Prostate-specific antigen spikes after permanent prostate brachytherapy |
| Q34572064 | Radiation for prostate cancer. |
| Q33853716 | Radiation therapy options in the treatment of prostate cancer |
| Q41727438 | Radioisotopic implantation for carcinoma of the prostate: does it work better than it used to? |
| Q41737325 | Radiotherapy options for localized prostate cancer based upon pretreatment serum prostate-specific antigen levels and biochemical control: a comprehensive review of the literature |
| Q33745664 | Recent advances in the treatment of prostate cancer |
| Q36177602 | Recommendations of the American Association of Physicists in Medicine regarding the impact of implementing the 2004 task group 43 report on dose specification for 103Pd and 125I interstitial brachytherapy |
| Q74300566 | Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer |
| Q50249462 | Short-term outcome after high-intensity focused ultrasound in the treatment of patients with high-risk prostate cancer |
| Q63966178 | Surveillance after prostate focal therapy |
| Q34226325 | Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer |
| Q74305918 | Temporary PSA rises and repeat prostate biopsies after brachytherapy |
| Q73104124 | The effect of disease and treatment-related factors on biopsy results after prostate brachytherapy: implications for treatment optimization |
| Q53290530 | The utility of transition zone index in predicting acute urinary morbidity after 125I prostate brachytherapy. |
| Q83177323 | Transperineal image-guided permanent brachytherapy for localized cancer of the prostate |
| Q77509487 | Ultrasonically guided interstitial brachytherapy for prostate cancer: care of the patient in ambulatory surgery |
| Q30436660 | Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy |
| Q74459140 | [Clinical and biological surveillance after radiotherapy for localized prostate cancer] |
| Q95340841 | [Prostatic brachytherapy: an alternative therapy. Review of the literature] |